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Introduction
Interphotoreceptor retinoid-binding protein (IRBP), also known as retinol binding protein
3 (RBP3), is a major soluble protein found in the human eye and has been found to be associated
with mitigation of oxidative stress in patients with diabetic retinopathy (DR)1. DR is an ocular
condition caused by elevated blood glucose and is the leading cause of vision loss in adults aged
20-74 years2. One of the primary mechanisms of damage is oxidative stress, especially in the
early stages of DR due to a buildup of reactive oxygen species (ROS)3. Other mechanisms that
contribute to microvascular changes seen in DR stemming from hyperglycemia include advanced
glycation end product (AGE) formation and protein kinase C (PKC) dysfunction. While this is
well understood, it has long been thought that the first stage of pathogenesis of DR is a result of
oxidative stress on the microvasculature of the retina. New evidence shows that this may not be
the case, as damage may occur in the photoreceptors before any microvascular disturbances4.
The results of these early changes may not be observed symptomatically by patients or clinically
by practitioners, which has contributed to the under acknowledgement of photoreceptor damage
early on in the course of DR4.
Current research has begun to uncover this importance of the IRBP protein to reveal its
protective role in DR. The purpose of this article is to summarize the current research and
findings about IRBP, specifically those relating to its protective role and function from oxidative
stress seen in patients with DR. It is known that photoreceptors are susceptible to damage by
ROS as retinal cryosections stained with dichlorofluorescein show that the segment of the retina
contained the highest levels of ROS is the subretinal space4. One of the reasons for this pertains
to the significant light exposure photoreceptors endure over the course of a lifetime5.
While oxidative stress may be instrumental in the early stages of DR, what is it about
IRBP that has gained interest and prompted further investigation into its possible role in the
pathogenesis of the disease? It appears that IRBP concentrations fluctuate throughout the course
of DR, more specifically, levels of IRBP decrease as the disease progresses6. This information
suggests that decreased IRBP may be associated with progression of DR, but alone does not
entirely support its protective role and justify the increased interest into the protein. More
promising is that IRBP has been shown to provide protection from oxidative stress on
photoreceptors1 in mice in various treatment settings. This information contributes substantially
to the possible protective role of IRBP, providing promising evidence to encourage further
research.
It is important to further our understanding of this protein as its possible protective effects
could contribute to an effective and even personalized treatment for patients with DR. The
efficacy of antioxidant treatment in patients with DR has not been demonstrated in recent
studies, but this could be due to a lack of studies investigating comprehensive antioxidant

possibilities or simply because treatment was initiated too late4. There is also a lack of
implementation of correct imaging studies to assess oxidative stress. Evidence shows that there is
a link between oxidative stress and early photoreceptor damage; which suggests that further
investigation into the development and implementation of effective imaging, as well as
personalized antioxidant treatment, should be carried out4.

Fig. 1. Overview diagram of the consequences of chronic hyperglycemia which lead to vision loss in diabetic retinopathy.

Interphotoreceptor retinoid-binding protein
In the eye, IRBP can be found in primarily two locations: the interphotoreceptor
extracellular matrix (IPM)7 and the vitreous8. The specific anatomical compartment where the
IPM is located is defined as the extracellular space between photoreceptors and the retinal
pigment epithelium (RPE)9. IRBP is produced by rod and cone cells. Photoreceptors synthesize
IRBP, through the retinoid exchange between RPE and photoreceptors, seen in the classic visual
cycle10. It has been shown that rod and cone photoreceptors are the primary site of production of
IRBP in early development of the eye.
Most of our current understanding of IRBP pertains to concentrations found in the IPM,
where it performs essential functions in the visual cycle11. The purpose of IRBP in this location
is primarily to assist in the metabolism and delivery of retinoids between photoreceptors and
protecting them from oxidation secondary to ROS12. The essential role of IRBP involves the
efficient transport and delivery of retinoids
(specifically 11-cis, all-trans retinol and 11-cis
retinal) to rods, cones, RPE, and Müller cells
which are essential for proper function of the
visual cycle12. The hypothesized protective
function of IRBP involves transport and clearing
of retinoid metabolites which can accumulate over
time with chronic light exposure13. These retinoid
metabolites, such as all-trans-retinal (atRAL)14,
can produce ROS that cause oxidative stress and
can lead to degradation of photoreceptors3,15.
The source of IRBP found in the vitreous
is
not
fully
understood. IRBP mRNA has been
Fig. 2. Homology modeling of bIRBP module 4 with a molecule
found in the ciliary epithelium, suggesting an
of all-trans retinol (purple) attached to ligand-binding site
(Gonzalez-Fernandez, et. al., 2014).
origin of production of IRBP found in the
vitreous16 Another production site may be the RPE, as a study by Garcia-Ramirez demonstrated
that IRBP mRNA was found in neuroretinal and RPE samples in rats, suggesting that the RPE
also contributes to IRBP concentration in the vitreous8. Its function and purpose in the vitreous
are unknown, but levels of IRBP in the vitreous have been found to fluctuate throughout the
course of patients with DR1.
Reduced IRBP Expression
and DR
In order to further
understand the possible
protective benefit of IRBPs
essential nature in the
mitigation of DR, it is
important to examine
relationship between IRBP
levels and severity of the
disease.

Fig. 3. Diagram demonstrating the decreased
production of IRBP in patients with diabetes and
progression to diabetic retinopathy.

Reduced
production of
interphotoreceptor-retinoid binding protein (IRBP) has been reported in DR patients, however,
the mechanism leading to its decline is currently unknown8. Even though it has been shown that
photoreceptors produce IRBP, it is still unclear whether the downregulation is a direct
consequence of photoreceptor dysfunction found in the early stages of DR as opposed to other
mechanisms, such as dehydration of the IPM4 or Müller cell dysfunction1,17. Previous studies
have linked the loss of photoreceptors and retinal degeneration in which the IRBP is decreased
possibly causing photoreceptor damage thus leading to retinal neurodegeneration in the
Abyssinian cat18. This finding poses significant value to the determination of therapeutic protein
targets in prevention of IRBP loss seen in non-proliferative diabetic retinopathy (NDPR) patients
in the visual cycle.
Knockout (IRBP -/-) mice revealed a loss of photoreceptors and profound changes in the
interphotoreceptor matrix and outer segments. When comparing mRNA levels of IRBP between
diabetic and non-diabetic mice retinas, the diabetic retinas exhibited a significant under
expression of IRBP. This finding suggests that the downregulation of IRBP occurs even before
the development of DR. Garcia-Ramirez demonstrated that proliferative diabetic retinopathy
(PDR) and non-proliferative diabetic retinopathy (NPDR) patients have decreased intravitreous
IRBP than non-diabetics8.
Detection of decreased expression of IRBP in the diabetic animal model

Decreased IRBP expression in diabetic mice secondary to retinoid metabolism disruption
Current findings pertaining to the early pathological process of DR suggest that defects in
visual function can be seen before diabetic patients even experience microvascular structural
changes19, such as dot blot hemorrhages, cotton-wool spots or macular edema20. One noted
visual deficit that can be seen before microvascular changes is delayed dark adaptation. Visual
perception begins with the absorption of a photon by a chromophore called 11-cis-retinal21. What
is referred to as a key step in the pathway of the visual cycle, is the isomerization of 11-cisretinal between the retinal pigment epithelium (RPE) and the photoreceptors22. In order for 11cis-retinal to enter a photoreceptor, it first needs to cross the IPM with the help of IRBP. IRBP is
secreted from photoreceptors, therefore its absence or any photoreceptor dysfunction would
hinder the 11-cis-retinal chromophore from delivering and binding to opsin to regenerate visual
pigments.
Using diabetic rat models, Malechka et. al. (2017) assessed the impact of diabetes on the
visual cycle and metabolism of retinoids in the eye. After inducing diabetes in rats for 4 months,
ERG results revealed significantly reduced a- and b- waves compared to nondiabetic controls.
This reduction in amplitudes suggests photoreceptor function becomes impaired as a result of
diabetes. Additionally, 11-cis-retinal levels were quantified in the diabetic rat eyes showing a
decrease of about 30% compared to the nondiabetic controls19. Given that 11-cis-retinal is
essential for the formation of visual pigment, its deficiency may contribute to photoreceptor
degeneration. Conclusions couldn’t be drawn on whether the low 11-cis-retinal production was
attributed to a deficient visual cycle. However, analyzing the expression of visual cycle protein
IRBP could grant insight on the mechanism. A retinoid profile collected by Malechka et. al.
(2017) analyzed the eyecups of dark-adapted diabetic rats and found down-regulation of a key
protein, IRBP. Additionally, other key visual cycle proteins, including retinol-binding protein 4
and retinoids19 were found to be decreased further supporting the notion that DR disrupts the
visual cycle. Suggesting, that IRBP is essential in the visual cycle to protect 11-cis-retinal from

photodegradation and decreased levels of IRBP may contribute to reduced chromophore levels.
Although results from this study provided the first evidence that retinoid metabolism becomes
disturbed in the diabetic eye, the mechanism of how diabetes downregulates visual cycle proteins
remains to be further investigated.
Reduced IRBP expression in human diabetics
Hyperglycemia is known to increase ROS through different mechanisms, but its primary
source is suspected to be the mitochondria, which causes a buildup of ROS due to increased
glucose metabolism3. It may seem that increased production of ROS secondary to
hyperglycemia is sufficient to explain the severity of damage seen in patients with DR. However,
other evidence shows that there may be other endogenous factors extenuating the negative
impact and possibly slowing the progression of DR.
A study by King et. al. (2011)23, contributed to this notion through analysis of the Joslin
50-year Medalist cohort, composed of individuals with insulin-dependent diabetes for 50 years
or more. The results demonstrated that 35% of patients did not exhibit complications of diabetes
such as retinopathy, nephropathy, or neuropathy despite similar glycemic control23. Considering
the extensive history of diabetes of these patients, these finding were unexpected and insinuated
that there may be other factors at play involved in protection from the negative effects of
hyperglycemia in long-term diabetic patients. This study inspired Yokomizu et. al. (2019) to
investigate what, if any, underlying endogenous protective factors exist. A study investigating
IRBP and three other proteins, was done to evaluate the medalist patients who did not exhibit
significant signs of chronic diabetic damage1. Yokomizu et. al. (2019) decided to focus on IRBP
as their primary suspect of endogenous protection, due to prior evidence associating decreased
levels of IRBP and photoreceptor degeneration1,8,18. Patients in the Medalist cohort study were
divided into two groups, none to mild NPDR and patients with PDR for vitreous and retina
evaluation. The samples were analyzed by mass spectrometry revealing levels of IRBP in
patients with mild to no NPDR were 1.6 times higher in the retina and 1.9 times higher in the
vitreous when compared with the PDR group. The vitreous samples were evaluated further
between a larger cohort of subjects divided into NPDR and PDR groups which revealed no
significant correlation between the patient’s hemoglobin A1c (HbA1c)1. It is important to review
these values as they help confirm the notion that severity of diabetic eye disease was not strictly
mediated by glycemic control and that other endogenous factors play a role in mitigating the
severity of DR.
Effect of anti-Vascular Endothelial Growth Factor medication on the production of IRBP
Anti-Vascular Endothelial Growth Factor (VEGF) ocular injections are often
administered to patients with DR and macular edema24, for the past few decades. Vascular
endothelial growth factor (VEGF) is an endothelial growth factor that promotes angiogenesis by
enhancing endothelial cell proliferation and migration25. The use of this medication has been
supported by studies which have shown that these injections can improve edema secondary to
diabetic eye disease and even lead to regression of DR24 by targeting microvascular growth. New
research on the impact of anti-VEGF treatment on the production of IRBP suggest that there
might be negative effects on IRBP26. This was uncovered by a study performed by Shen et. al.
(2017) using Y79 photoreceptors subjected to hypoxic stress in order to test the effects of
ranibizumab (Lucentis – binds VEGF-A receptors 1 and 2) and aflibercept (Eylea – binds VEGFA, VEGF-B, and placental growth factor [PLGF] directly), two common anti-VEGF

medications. Y79 photoreceptor cells, human retinoblastoma cells, serve as a model system for
photoreceptors as they can differentiate into photoreceptors and express rod-cell specific genes27.
Y79 cells are known to produce IRBP, which can be expected from photoreceptor cells26. A
significant reduction of IRBP was found in hypoxic conditions, regardless of glucose
concentration and in the absence of treatment which served as a baseline for the experiment. The
first experiment treated Y79 cells with anti-VEGF medications in normoxic conditions which
resulted in decreased production of IRBP, more profoundly with aflibercept than ranibizumab.
This is thought to be due to the greater impact aflibercept has on the expression of mitochondrial
and cytoplasmic markers Hsp60, HSP90 and TRX1 and TRX226, which are essential for cell
viability28. Interestingly, ranibizumab and aflibercept further inhibited the production of IRBP
when administered to the cells under hypoxemic stress. This decrease in production was even
more significant than the decrease observed in hypoxic conditions alone. When comparing the
two anti-VEGF medications, aflibercept exerted less IRBP inhibition than ranubizumab26, which
is opposite of the results seen in normoxic conditions. This could be explained by the
mechanistic differences between the two medications, as aflibercept inhibits VEGF-A, VEGF-B,
and PLGF (angiogenic factors) while ranibizumab specifically inhibits the action of only VEGFA. Since ranibizumab has a less potent anti-VEGF effect compared to aflibercept, aflibercept
may prevent a decrease in IRBP production as a result of increased VEGF production seen in
DR1 (hypoxic setting).
It has been previously reported that under hypoxic conditions photoreceptors have
increased production of VEGF, along with other inflammatory cytokines, in diabetic eye29. It is
interesting to note that the overexpression of VEGF caused by photoreceptors in turn drives a
reduction of IRBP production, but those same photoreceptors that synthesize IRBP require this
protein for the visual cycle. Aflibercept seems to be the most promising treatment, as the
findings of Shen et. al. (2017) suggests that aflibercept may partially protect against the
inhibitory effects of hypoxia-induced VEGF overexpression on IRBP26.
To this point we have reviewed the association between decreased IRBP and
photoreceptor degeneration in both mice8 and Abyssinian cats18. In humans, we found that
hyperglycemia alone was not sufficient to dictate the severity of DR and that there might be
other protective endogenous factors mitigating the damage23. Further evaluation of the same
human cohort demonstrated an inverse relationship between severity of DR and IRBP levels in
the vitreous and retina1. The Malechka study further supports the impact of DR on the production
of IRBP and dysregulation of the visual cycle through neuroretinal monitoring. Finally, Shen et.
al. (2017) uncovered that even patients treated for DR with anti-VEGF medication may be at
increased risk of damage from the disease as well. Anti-VEGF therapy, although beneficial to
prevent angiogenesis in DR patients, may lead to decreased expression of IRBP. This recently
discovered effect of a widely used class medications suggest further investigation should be
performed in order to truly evaluate the efficacy of anti-VEGF treatments.
Over Expression of IRBP and DR
Information from this accumulating evidence gave strong support for the idea that IRBP
may play a role in protection from DR. While promising, this evidence is not sufficient to truly
link the protective role of IRBP in DR. The next important step is to evaluate whether or not
increased levels of IRBP could possibly reverse the retinal damage imposed by diabetes.

Treatment with increased IRBP in rats and mice
The same study by Yokomizu et. al. (2019) that found elevated levels of IRBP in
Medalist patients with decreased severity of DR tested the notion of IRBP’s protection through
translational experiments. They tested this through three experimental methods: intravitreal
injection of IRBP, subretinal stimulation of IRBP production via subretinal injection, and gene
modification to induce increased expression of IRBP.
Intravitreal Injection of IRBP
Yokomizu et. al. (2019) tested the impact of exogenously injected IRBP into the vitreous
of Lewis rats in order to compare the level of retinal vascular permeability (RVP) between rats
with diabetes and those without. The goal was to test whether or not elevated levels of IRBP (2.5
μg/ml) compared to normal, non-diabetic vitreous levels (1-2 μg/ml) would serve a protective
effect on rats with a two-month history of induced diabetes with the primary outcome measure
being reduction of RVP. The results showed that after a three-day period of treatment, the
diabetic mice group had a reduced RVP to levels similar to rats without diabetes. These results
demonstrated a positive impact, increased levels of IRBP have on the microvasculature but the
benefits did not stop there. Electroretinograms (ERG) were performed on the rats to evaluate
neuroretinal changes before and after treatment with intravitreous IRBP. ERG was used to
measure electrical response from the retina, specifically providing functional information
pertaining to photoreceptors30. The baseline ERG of rats with diabetes showed a decreased
amplitude of oscillatory potential when compared to non-diabetic rats, but ERG results after
treatment with IRBP showed improved amplitudes. These findings demonstrate that IRBP also
serves a neuroretinal protective function, additional to vascular complications. ERG results were
also obtained from the non-diabetic group which also showed an improvement in amplitudes
from baseline, further supporting this notion. One aspect of DR that did not improve was retinal
thinning, as the injections did not seem to impact this aspect of the retina through the course of
disease.
Subretinal stimulation of IRBP production via subretinal injection
The second study performed involved injection of a lentiviral vector containing IRBP
genetic material over a six-month period in diabetic rats1. The purpose of this study was to
compare baseline ERG and optical coherence tomography (OCT) in order to evaluate the
primary outcomes which included neuroretinal light response and retinal thinning, respectively.
After treatment, levels of IRBP were measured in both groups and found that the diabetic nongroup decreased expression of IRBP while the treated diabetic group exhibited similar levels of
IRBP found in non-diabetic controls. The diabetic rat group which was not treated over the sixmonth period showed a decrease in ERG amplitudes in response to light stimuli. In the treated
diabetic rat group, a decrease in ERG response was actually prevented by the overexpression of
IRBP. Similar results were found on OCT regarding retinal thinning, as the diabetic mice who
overexpressed IRBP did not exhibit retinal thinning in comparison to the non-treated group1.
Gene modification
A final approach in this study by Yokomizu et. al. (2019) was performed in order to
evaluate increased levels of IRBP outside the setting of intraocular injections. In order to
accomplish this, IRBP transgenic mice were generated to specifically overexpress hIRBP in
photoreceptors. IRBP levels in the transgenic mice were found to be expressed 1.7-fold greater

when compared to wild type mice. Both groups of mice received streptozotocin treatment in
order to induce diabetes over a two-month period. After this two-month period, levels of mIRBP
expression were measured and the diabetic +transgenic mice exhibited a 1.8-fold increase in
expression when compared to wild-type diabetic mice. ERG and OCT were performed in both
groups. Similar to results from IRBP injection and transfection approaches, overexpression of
IRBP provided protection from decreased ERG amplitude and retinal thinning, in comparison to
the wild-type diabetic group. Additionally, RVP was also measured in this group in order to
compare with results from the first study, it was found that the diabetic transgenic mice exhibited
no RVP and also decreased the formation of acellular capillaries in the retina by 58% when
compared to the wild-type diabetic mice.
The thorough study performed by Yokomizu et. al. (2019) proved to be significant in that
it showed increased levels of IRBP were able to demonstrate a protective effect on
photoreceptors by measuring ERGs, which is consistent with the hypothesis that IRBP may have
protective effects on photoreceptors. Two additional findings that support IRBP’s protective role
further included structural improvements, as RVP decreased and in the case of subretinal
stimulation with a lentiviral vector retinal thinning did not occur.
Simvastatin-induced production of IRBP
The previous study1 was highly insightful into the potential benefits of IRBP as they
directly studied the impact of IRBP pertaining to protection of the retina from vascular and
neuroretinal damage. Another study by Zhang et. al. (2019) evaluated protective benefits of
IRBP on photoreceptors indirectly by monitoring photoreceptor function and IRBP levels after
the treatment with simvastatin. While simvastatin is primarily used as a cholesterol lowering
agent, previous studies have demonstrated that it exhibits protective effects on the central
nervous system which has led to further investigation into using simvastatin as a treatment for
various neurodegenerative diseases14.
The mechanism of neuroprotection from simvastatin on photoreceptors is not entirely
understood. The study by Zhang et. al. (2019) evaluated levels of two photoreceptor-specific
markers, CRX and IRBP, as they have been associated with mitigation of oxidative stress. While
this article has discussed the antioxidant properties of IRBP, CRX itself functions as a
transcription factor for multiple proteins, one of which being IRBP31. The study hypothesized
that simvastatin would exhibit a neuroretinal protective effect by increasing levels of IRBP and
CRX in the human retina via increased production from photoreceptors. IRBP and CRX levels
were tested specifically via two experiment models: ex vivo and in vivo.
Ex vivo
The ex vivo study was executed by treating human retinal explants with 5 μM of
simvastatin for 16 hours the outcomes were then measured in accordance with the controls for
having any change in IRBP and CRX levels after treatment. The results showed that retinal cells
treated with simvastatin showed significant increased expression of IRBP and CRX, confirming
that simvastatin upregulated the expression of IRBP in the human retina. In order to confirm
whether or not this provided photoreceptor protection from oxidative stress, another test on
human retinal explants was performed, though this time photoreceptors were exposed to the
ROS, atRAL, for 6 hours. IRBP is required to prevent the accumulation of atRAL, protecting the
retina from the inflammation, oxidative stress, and mitochondrial dysfunction2 which is one of

the reasons it was selected for this study14. One group of retinal explants received pretreatment
with simvastatin 5 μM for 4 hours while the other group did not receive pretreatment. Analysis
via TUNEL assay performed after exposure to atRAL revealed an anti-apoptotic effect on
photoreceptors in the treatment group than compared to the non-treated group, as significantly
more cells stained positive in the simvastatin treated group.
In Vivo
Prior evidence has shown that Müller cells also have regulatory impacts on the
concentrations of IRBP in the IPM17. Müller cells are glial cells in the retina which play an
important role in maintaining the health and function of the human retina32. The in vivo study
treated mice with tamoxifen in order to disrupt Müller cells, which resulted in increased
photoreceptor degeneration and decreased IRBP expression. The treatment group of mice were
fed simvastatin for 1 week before treatment with tamoxifen, the retinas were collected, and
studied one week after degeneration. The group which received pretreatment with simvastatin
showed significant attenuation of the downregulation of IRBP and CRX typically seen in retinas
with disrupted Müller cells. Not alone, the pretreatment group also demonstrated preservation of
peanut agglutinin-stained structures, which signifies decreased photoreceptor degeneration and
suggests that simvastatin can slow the progression of photoreceptor degeneration secondary to
Müller cell disruption.
This study by Zhang et. al. (2019) showed promising evidence that simvastatin could
have potential treatment efficacy for protection against oxidative stress in patients with diabetic
eye disease while strengthening the connection of IRBP to this protective role. At the end of the
study, results from the in vivo and ex vivo tests were compared and were found to have slightly
different results which were attributable to using different concentrations of simvastatin. The ex
vivo group demonstrated significant neuroretinal protection by receiving a higher dose of
simvastatin, 5 μM, while the in vivo experiment used a lower dosage of simvastatin (unspecified
dosage) and was only able to slow the progression of the disease. These finding suggests that
different levels of simvastatin may exhibit different effects, and that higher doses of simvastatin
may be needed to treat neuroretinal degeneration secondary to oxidative damage. Further studies
must be performed in order to evaluate appropriate levels of simvastatin to be used as a possible
treatment for neuroretinal disease.
Oxidative Stress and Protective Roles of IRBP
The final segment of this article will go over the oxidate stress and its mechanism of
damage, along with the proposed mechanisms of protection IRBP provides against it. To start,
we will review current knowledge on ROS, the byproducts of various metabolic pathways that
can contribute to oxidative stress.
Reactive Oxygen Species - Production and Definition
The main source of ROS produced endogenously come as byproducts from the electron
transport chain in the mitochondria3, which is an essential pathway for the production of ATP in
the human body. Exogenous sources are also responsible for the generation of ROS and include
tobacco smoke, ethanol, and fatty acids in foods3. In low concentrations, ROS function by
altering protein structures, changing their conformation and altering their function which is
essential for various cell signaling pathways such as RAS and protein kinase C3. With that in

mind, as ROS builds up in the body it can cause unbalanced increased ROS which can lead to
damaging outcomes, as demonstrated previously in the article. ROS involves a wide range of
molecular formations which include oxygen and free radicals, such as superoxide and hydroxyl
which contain unpaired electrons. On the other hand, oxidizing agents such as hydrogen peroxide
and hypochlorous acid are related to ROS but are not considered free radicals as they do not
contain an unpaired electron.
ROS Damaging Mechanisms
These molecules are highly reactive, hence their name and can exert negative effects in a
multitude of ways, most significantly by binding to DNA or damaging lipid membranes. When
bound to DNA mutations can occur, which is usually not significant in low doses as endogenous
repair mechanisms can fix these mutations before significant impairment. If ROS build up
become uncontrolled, the DNA mutations can become more frequent leading to significant cell
pathologies ranging from cell dysfunction to malignancy. When ROS binds to the lipid
membrane on cells they can cause a rupture causing cell swelling and lead to apoptosis via
various apoptotic mechanisms.
Evidence of IRBP protection from oxidative stress and ROS
While research is still being performed on IRBP and its possible protective mechanisms
against oxidative stress secondary to ROS, substantial evidence has already been found to
support this notion. This review has discussed how IRBP was able to prevent photoreceptor
degeneration from atRAL, when treated with simvastatin, as simvastatin increased IRBP levels14
and demonstrated possible treatment options in the future.
Possible mechanisms of how IRBP could protect the retina from ROS have been
suggested1,4,15,33, however important to first understand how IRBP prevents the production of
ROS, such as through atRAL. As retinoids cross the IPM, they are typically exposed, potentially
damaging elements to light, oxygen, and free radicals34. Given our knowledge on the function of
IRBP and how it assists in the transport of retinoids12, it could be possible that IRBP serves its
protective function here by preventing increased retinal to elevate ROS due to the exposure of
harmful elements in the IPM.
More important is the direct impact IRBP can have on the protection of photoreceptors
from ROS. A study by Lee et. al. (2016) demonstrated the direct connection of IRBP and its
protection against atRAL by measuring atRAL levels and retinal damage in IRBP-/- mice after
exposure to light35. The results showed that the knockout mice displayed significantly higher
levels of atRAL, cell death, and an increased inflammatory response (increase TNFa)35. All of
these effects were significantly attenuated in the wild-type mice who produced normal levels of
IRBP. This evidence is extremely promising and shows a direct protective effect of IRBP against
damage from ROS. These tests should be repeated in the human retina model in order to gain
further insight and consideration of possible treatments in patients with DR. Additionally, this
could potentially give insight and confirmation of IRBPs protective abilities.
Specific Damage Mechanisms and IRBP Protection from DR
Now that we have discussed the direct impact IRBP has on the protection of retinal
damage from ROS, we will now go into more specific damage mechanisms that are suspected to
occur in the retina and follow with evidence of how IRBP may serve a protective function
against these specific mechanisms.

ROS-induced Photoreceptor Structural Damage and IRBP
ROS can be found in various parts of the human body; however, the retina is highly
susceptible and important when considering the negative impacts of ROS as it has the highest
oxygen demand of any organ in the body. This oxygen-heavy environment is highly conducive
to the formation of ROS13 due to the increased metabolism and demand found in the retina. Not
only that, the retina is exposed to a high intensity of light, which is also associated with the
increased production of ROS5. These two factors, along with others, make the retina especially
susceptible to buildup and subsequent damage from ROS in the healthy human retina.
Photoreceptors are chronically exposed to light and its exposure to ROS is increased with
age, which is expected in a healthy human. The polyunsaturated fatty acid composition of
photoreceptor cell membrane provides an ideal substrate for ROS binding, which increases
photoreceptor sensitivity to ROS significantly3. Light exposure over time has been shown to lead
to lipid peroxidation of the photoreceptor cell membranes, upregulation of antioxidant proteins
(heme oxygenase 1), and later cause apoptosis of the photoreceptors3,15.
Not only did this study demonstrate damage mechanisms of ROS on photoreceptors, it
also tested the benefits of antioxidant therapy on photoreceptors with long term exposure to
ROS. Rats exposed to stress from ROS secondary to light exposure were evaluated in an
additional experiment which revealed reduced photoreceptor cell death when treated with
antioxidant therapy15. Since this study did not isolate any antioxidant as the primary agent in this
protective mechanism, we cannot attribute antioxidant protection to IRBP directly. Moreover,
given our knowledge on the function of IRBP and its protective role against oxidative stress, it is
possible that this evidence would be applicable to IRBP. The primary mechanism of IRBP
protection of photoreceptors pertains to its function of the transport of retinoids and their
metabolites such as atRAL, which can produce ROS in photoreceptors14,35. This function serves
to both provide essential components for photoreceptor survival while also protecting the
photoreceptors from buildup of ROS, which can exert the aforementioned complications.
IRBP Regulation of Lipofuscin Precursor Production in the Retina
As we age, certain morphologic changes occur on the microscopic level and can vary
depending on the anatomical location of the body. Lipofuscin is a lipopigment formed by lipids,
misfolded proteins, and metals36, and is one of the primary microscopic morphologic findings
which tend to accumulate in patients as they age. Ultimately, as lipofuscin accumulates in
lysosomes, it can lead to cytoskeletal, metabolic, and cellular trafficking dysfunction and
ultimately neuronal loss36.
In the retina, an important precursor of lipofuscin is atRAL37, an ROS species that can
exhibit many damaging effects on the retina and is metabolized by IRBP. atRAL production is
increased during metabolism of retinoids with light exposure and can interact with outer segment
components, leading to lipofuscin precursor formation37. Ultimately, as lipofuscin accumulates
in lysosomes, it can lead to cytoskeletal, metabolic, and cellular trafficking dysfunction and
ultimately neuronal loss36. Since IRBP is known to metabolize atRAL, it would make sense to
think that IRBP serves a protective role against the aging process of lipofuscin accumulation. A
study by Chen et. al. (2017) showed that clearance of atRAL and decreased formation of
Lipofuscin precursors was associated with increasing IRBP concentrations, giving strong
evidence in support of this idea.

These findings contribute further insight into the important role IRBP plays in the
protection of the retina. It appears that this protective role extends beyond the setting of disease,
but also protects against the natural process of aging experienced by everyone. Considering
IRBP levels decrease in the setting of DR, it is also possible that this aging process could be
accelerated in these patients due to increased lipofuscin formation secondary to IRBP loss. This
also shows another specific mechanism of protection IRBP provides for the retina - decreasing
lipofuscin precursor formation. This effect is important in preserving the natural metabolic and
structural components of cells, prolonging longevity.
ROS-induced Damage in Photoreceptor L-type Calcium Channels and IRBP
Another proposed mechanism of photoreceptor damage involves dysfunction of rod Ltype calcium channels (LTCC) as such findings have been seen in rats with high levels of ROS4.
These channels are important in regulation of neurotransmitters in the first retinal synapse and
are essential for light/dark adaptation in photoreceptors. As these channels are damaged, waste
products such as CO2 and water are not properly excreted into the subretinal space (and
concomitantly, the IPM), which leads to dehydration. Dehydration alters the concentrations of
molecules in the IPM, such as IRBP, further dysregulating the protein and contributing to an
increase of ROS in the subretinal space.
Damage to LTCC is another study which has been connected to the antioxidant function
of IRBP and supports its protective role. This finding also suggests that IRBP is not only
essential for the maintenance of photoreceptor function, but that it also plays an important role in
maintenance of IRBP concentration. This contributes to the idea that IRBP is not only essential,
but that it could be considered fragile, as failure of its own mechanisms of protection ultimately
leading to dysregulation and dysfunction of IRBP itself.
Müller Cells and IRBP
As demonstrated in the study by Zhu et. al. (2015), Müller cell dysfunction can lead to
decreased expression of IRBP through mechanisms which are not entirely understood. One
mechanism of Müller cell damage in patients with DR involves advanced glycation end products
(AGEs)3 which accumulated secondary to overloaded glucose metabolism in patients with
diabetes and hyperglycemia38. AGEs can sequester in Müller cells which causes increased
production of glial fibrillary acidic protein, nitric oxide, and glutamate synthesis, which can lead
to toxicity due to neuronal over excitation3.
Mitigation of damage to Müller cells by IRBP was tested by Yokomizu et. al. (2019) in
an effort to find a link between IRBP’s ability to bind and GLUT1 transporters in order to
decrease glucose uptake. Müller cells were incubated for one hour with IRBP and 3-O-methyl-Dglucose (3-O-MG) and 2-deoxy-D-glucose (2DG), two forms of glucose and the results showed
that IRBP decreased the uptake of 3-O-MG and 2DG by 65%, demonstrating a protective
property of IRBP against excessive glucose uptake in Müller cells. This mechanism is unique,
considering the focus of this article, as it pertains to direct protection from ROS and oxidative
stress by IRBP. However, by protecting Müller cells it is possible that the maintenance to
produce IRBP may benefit from its protective effect on Müller cells.
Protecting Müller cells, by maintaining its production is complementary to the role as
IRBP mentioned in the protection of LTCC in photoreceptors. A possible conclusion that can be
derived from this evidence is that IRBP plays an important role in the maintenance of both its
production and adequate concentration in the IPM. This suggests that once a buildup of ROS

exceeds the IRBP’s metabolic ability, its production and function will begin to decline.
Essentially, IRBP serves an important protective role in its production that goes beyond its
general purpose of photoreceptor protection.
Overall, being that ERGs measure the function of photoreceptors by measuring electrical
activity of the retina, these results suggest a photoprotective effect of IRBP. In the Yokomizu
and Malechka experiments which are discussed earlier, neuroretinal function was found to be
improved through analyzing ERG results after treatment with IRBP. This suggests an objective
measurement to prove the efficacy of IRBP treatment in the preservation and protection of
photoreceptors.

Fig. 4. Diagram of the mechanisms which contribute to decreased IRBP expression in patients with chronic hyperglycemia.

IRBP Protective Role in the Visual Cycle
The majority of the protective mechanisms discussed so far pertain to protection from
damaging mechanisms resulting from the accumulation of ROS. That being said, IRBP also
plays a protective role in the visual cycle by facilitating its function through the transport of
retinoids. The original theory of the role of IRBP in retinoid transport was that IRBP solely
functioned as a transport protein which facilitated the diffusion of retinoids across the IPM33.
While this alone demonstrates an important role of IRBP in the visual cycle, it appears that the
function of IRBP goes beyond this initial idea.
Studies involving spectroscopy have shown that retinoids degrade when exposed to
light39, which is problematic as retinoids are essential to the visual cycle and photoreceptor
function. This spurred a new theory that IRBP may serve a protective role on retinoids against
photodegradation. This effect is most important in high flux conditions which can be observed in
the visual cycle33, more so in the cone visual cycle than that of rods. This may be due to the high
retinoid demands of cones during light exposure, in turn increasing the risk of degradation.

Not only does this protective role against photodegradation facilitate transport of
retinoids, it protects photoreceptors from further damage secondary to ROS, as increased
photodegradation of retinoids increases their cytotoxicity33. These findings are especially
promising when evaluating the vital role of IRBP in the protection and maintenance of the visual
cycle.
Conclusion
Evidence presented in this article provides a strong positive relationship between IRBP
production and mitigation of DR. The process begins with hyperglycemia which leads to
increase stress on the retina via increases ROS. As ROS levels rise, they begin to overload the
antioxidant function of IRBP and lead to its decreased production by damaging photoreceptors
and their surrounding matrix. This damage, combined with advance glycation end product
formation and protein kinase C dysfunction eventually leads to microvascular damage and
inflammation40. IRBP levels were higher in patients without DR as demonstrated in the
Yokomizu study, further supporting the notion that IRBP could play a role to mitigate the
development of DR.
The exact mechanism of decreased IRBP expression in DR is not fully understood, but
certain mechanisms have been proposed. Photoreceptors are one of the primary producers of
IRBP and degeneration of these cells secondary to ROS buildup is likely the primary mechanism
behind its decrease. Dysfunction of Müller cells may also contribute to this, as they begin to
produce inflammatory cytokines rather than the neurostimulators normally produced which are
essential for photoreceptor maintenance. Further investigation must be done in order to fully
understand the underlying mechanism of decreased IRBP production and DR.

The importance of better understanding the decrease of IRBP production in patients with
DR is due to the fact that IRBP plays an essential role in the metabolism of retinoids and ROS.
Since its primary purpose is to transport essential retinoids and manage harmful ROS products
from increased atRAL, decreased expression of IRBP can lead to significantly increased risk of
oxidative damage. The structure of IRBP is likely imperative to its antioxidant properties, as
demonstrated by the fact that an aspartic acid in normal human IRBP is replaced by asparagine in
a form of autosomal recessive retinitis pigmentosa12. This supports the antioxidant role of IRBP,
as patients with retinitis pigmentosa can suffer from permanent vision loss due to photoreceptor
loss. This information then presents us with the question of whether or not IRBP’s protective role
is a contributing factor to the disease, which could be a result of increased ROS buildup.
As evidence accumulates, it appears that IRBP is a significant factor in protection from
damage secondary to ROS buildup. As a consequence of ROS buildup, damage to the
photoreceptor membrane, excitatory calcium channels, and dysregulation of mitochondrial
function all contribute to apoptosis of photoreceptors. Further investigation is needed to solidify
this role of IRBP in order to possibly contribute to further treatment development in the future
for patients with DR.
There are many avenues to pursue when considering the future directions of IRBP,
especially when discussing its possible clinical applications. The majority of the evidence
presented discusses the association of IRBP and its protective role on retinal photoreceptors,
which suggests that it could be used as a treatment in the future. If IRBP is found to be effective
in the prevention of DR, the best method of administration would need to be investigated as well.
Ideas include direct intravitreal injection of exogenous IRBP or increasing the production of
endogenous IRBP via genetic stimulation, but there may be another unknown method which
would work best.
Outside of treatment, it is possible to consider the use of IRBP levels as a biomarker to
measure the progression of DR41. Since IRBP levels fluctuate throughout the course of DR, it
seems logical to use it as a biomarker for a condition which has little methods of detection early
in the course of disease. The main issue that presents itself with this is the best method of
obtaining IRBP levels, as it would need to be acquired from peripheral fluids41 in order to be
practical and affordable enough for general utilization. The application of the use of IRBP as a
biomarker is also challenged by the possibility that genetic production of IRBP may vary from
person to person23,41, making it challenging to rely on without a baseline measurement. It is
important to consider IRBP as a biomarker for DR as it would be extremely impactful in the
effort to identify DR early in the course of disease, before it exerts structural changes or, worse,
becomes symptomatic. Early detection could ultimately lead to significantly decreased vision
loss in a population which suffers from one of the highest rates of blindness in the Western
world. While there is some doubt about the use of IRBP levels as a biomarker, the idea is one
that should be investigated further in the future with the hopes that it could contribute to
decreased vision loss in patients with DR.
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